Allovate Therapeutics
Manufacturing · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
20 W 125th St Apt 1, New York, New York,...Phone Number
(844) 664-8669Website
www.allovate.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Allovate Therapeutics
Allovate Therapeutics is a New York-based biotechnology company founded in 2012 with the mission to improve allergy treatment for all patients.Explore more
Allovate Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Allovate Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Allovate Therapeutics
Product Launch: Get notified when Allovate Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Click to see if Allovate Therapeutics had a recent Job posting/layoffs
Allovate Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Allovate Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Allovate Therapeutics recently announced quarterly report
Check out if Allovate Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Allovate Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Allovate Therapeutics
Compare insights from companies similar to Allovate Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Allovate Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Allovate Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Allovate Therapeutics.
Allovate Therapeutics financials insights
Gather financial insights about Allovate Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Debt
$18K
Allovate Therapeutics Tech Stack
A closer look at the technologies used by Allovate Therapeutics
Allovate Therapeutics News & Media
Allovate Therapeutics Extends Free Allerdent® Program
Allerdent® Enables Patients to Maintain Allergy Immunotherapy During COVID-19 Pandemic Allerdent® Enables Patients to Maintain Allergy Immunotherapy During COVID-19 PandemicAllovate Therapeutics Provides Free Allerdent® To Physicians
Allerdent® Option Enables Patients to Maintain Allergy Immunotherapy During COVID-19 Pandemic Allerdent® Option Enables Patients to Maintain Allergy Immunotherapy During COVID-19 PandemicAllovate Therapeutics Appoints Bob Pomrenke as CEO
New York, April 02, 2019 (GLOBE NEWSWIRE) -- Allovate Therapeutics (“Allovate®”), a New York-based biotechnology company focused on improving treatment for allergies, is pleased to announce the appointment of Robert "Bob" Pomrenke to the position of Chief Executive Officer, effective April 1, 2019. Mr. Pomrenke brings over 25 years of sales, marketing and business development experience in the allergy immunotherapy market. He has held executive positions with Bayer Allergy PrAllovate Therapeutics Announces Grant of European Patent Covering Oral Mucosal Immunotherapy Platform
New York, March 08, 2019 (GLOBE NEWSWIRE) -- Allovate Therapeutics (“Allovate®”), a New York-based biotechnology company focused on improving treatment for allergies, is pleased to announce that the European Patent Office (EPO) has granted Patent No. 2563316 entitled, “Toothpaste for Allergic Desensitization via the Oral Mucosa.” The patent includes claims to the approach of combining allergenic proteins with toothpaste.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Allovate Therapeutics
Sign Up For FreeTo access detailed company insights
Allovate Therapeutics is a New York-based biotechnology company founded in 2012 with the mission to improve allergy treatment for all patients.... Read More
